Clinical Trial

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

Study acronym: DAN-RSV
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-09; most recent amendment 2026-05-27.
Status change: Recruiting → Active, Not Recruiting 2026-05-27
Status change: Active, Not Recruiting → Recruiting 2025-11-20
Status change: Recruiting → Active, Not Recruiting 2025-05-28
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06684743
Lead Sponsor Tor Biering-Sørensen
Collaborators: Pfizer
Conditions RSV
Enrollment 690,000 participants
Start Date 2024-11-18
Primary Completion 2028-05 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-29